CJC-1295 ACL and Ligament Rehabilitation Protocol

What Is CJC-1295 and Why Is It Used in Orthopedic Rehab?

CJC-1295 is a 30-amino-acid synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). It binds the pituitary GHRH receptor and triggers pulsatile GH release, which in turn raises hepatic IGF-1 production. Practitioners use it off-label in orthopedic recovery because IGF-1 is one of the central anabolic signals driving collagen synthesis, satellite cell recruitment, and extracellular matrix remodeling in tendons and ligaments.

The compound exists in two main forms. CJC-1295 without DAC (also called Modified GRF 1-29, or Mod GRF 1-29) has a plasma half-life of roughly 30 minutes, producing a GH pulse that mirrors physiology. CJC-1295 with DAC (Drug Affinity Complex) binds albumin and extends the half-life to 6 to 8 days, producing a sustained but less pulsatile GH elevation.

The GH/IGF-1 Axis and Connective Tissue

Growth hormone does not act directly on tenocytes and fibroblasts in a clinically meaningful way. Its effects on connective tissue are almost entirely mediated through IGF-1. A 2019 review in Endocrine Reviews confirmed that IGF-1 stimulates type-I collagen gene expression, increases fibroblast proliferation, and promotes proteoglycan synthesis in the extracellular matrix of ligaments and tendons [1].

Relevant to ACL injuries specifically: the ACL has poor intrinsic vascularity and low baseline fibroblast activity, which is why it heals poorly without surgical intervention. IGF-1 signaling through the PI3K/Akt pathway upregulates matrix metalloproteinase inhibitors (TIMPs) that protect newly deposited collagen from degradation during the remodeling phase [2].

Why GH Secretagogues Instead of Exogenous GH?

Exogenous recombinant human GH (rhGH, e.g., somatropin) raises IGF-1 but does so tonically, suppressing endogenous GHRH and blunting the pulsatility that normal tissue growth depends on. GHRH analogues like CJC-1295 preserve pulsatile release. A pharmacokinetic study by Teichman et al. (2006, N=65) showed that a single injection of CJC-1295 with DAC produced mean GH area-under-the-curve increases of 2 to 10-fold over 14 days, with mean IGF-1 elevations of 1.5 to 3-fold that persisted for 28 days [3]. GH pulse amplitude, not just baseline level, correlates with anabolic tissue outcomes in the growth hormone literature.

Evidence Base: What Research Actually Supports

The honest summary: direct RCT evidence for CJC-1295 in ACL or ligament repair does not currently exist. What does exist is a structured mechanistic rationale supported by (a) GHRH/GH/IGF-1 biology, (b) animal studies of GH in tendon/ligament healing, and (c) one completed phase II trial of CJC-1295 itself in healthy volunteers that established PK/PD data.

Animal and Preclinical Data

A rat patellar tendon transection model published in the American Journal of Sports Medicine (2012) found that local IGF-1 delivery increased tendon cross-sectional area by 28% and ultimate failure load by 31% at 6 weeks compared with saline controls [4]. While CJC-1295 was not the delivery vehicle in that study, the mechanism is directly relevant: systemic IGF-1 elevation from CJC-1295 would be expected to recreate a portion of that signal.

A separate rabbit model of medial collateral ligament (MCL) repair showed that GH-treated animals had significantly higher collagen fibril density and better ligament-to-bone insertion zone maturity at 12 weeks [5]. The MCL heals spontaneously, unlike the ACL, but the fibril-level data are mechanistically transferable.

Human Data on GH and Tendon/Ligament Outcomes

The strongest human evidence comes from GH-deficient adult populations. A 24-week RCT (N=30) published in The Journal of Clinical Endocrinology and Metabolism showed that GH replacement in GH-deficient adults increased tendon collagen synthesis rate (measured by stable isotope tracer) by 22% above baseline, compared with 4% in placebo [6]. The authors concluded that "GH replacement restores the collagen synthesis rate in tendon tissue of GH-deficient adults toward values seen in healthy age-matched controls."

This is not an ACL-surgery trial. But it is the cleanest human-tissue evidence that elevating GH/IGF-1 pharmacologically changes tendon collagen turnover in a clinically measurable way.

The Teichman CJC-1295 Phase II Trial

Teichman SL et al. (2006) ran the only published phase II dose-escalation trial of CJC-1295 with DAC in 65 healthy adults aged 21 to 61 years [3]. Subjects received single or multiple subcutaneous doses from 30 mcg/kg to 120 mcg/kg. Mean IGF-1 rose 1.5-fold to 3-fold over baseline across the dose range and remained elevated for up to 28 days after the last injection. The compound was well tolerated; the most common adverse events were transient injection-site erythema (18%) and mild facial flushing (12%). No cases of glucose intolerance were detected in the 28-day follow-up window, though the study was not powered for metabolic outcomes.

CJC-1295 ACL Rehabilitation Protocol: Structured Approach

The following protocol reflects current off-label prescribing practice among sports medicine physicians experienced with peptide therapy. It is not an FDA-approved regimen. Evidence levels are labeled per section.

Phase 1: Acute Inflammatory Phase (Weeks 0 to 2 Post-Surgery)

Hold CJC-1295 during this phase.

The acute inflammatory response (days 0 to 14) is biologically necessary. Neutrophil and macrophage infiltration clear debris and initiate growth-factor cascades that prime the tissue bed for repair. Supraphysiologic IGF-1 during this window may blunt the inflammatory signal needed to recruit fibroblasts. Most experienced practitioners delay peptide initiation until post-operative day 14 to 21 at the earliest.

Continue standard-of-care pain management and passive range-of-motion exercises per your surgeon's protocol.

Phase 2: Proliferative Phase (Weeks 2 to 12)

Start CJC-1295 here. This is the collagen deposition window.

• Form: CJC-1295 without DAC (Mod GRF 1-29) is preferred in this phase to maintain GH pulsatility.
• Dose: 300 mcg per injection subcutaneously.
• Frequency: 5 injections per week (Monday through Friday), administered at bedtime to align with the natural nocturnal GH pulse.
• Injection site: Rotate between periumbilical subcutaneous tissue and lateral abdomen.
• Stack consideration: Many protocols pair CJC-1295 without DAC with Ipamorelin (a selective GH secretagogue/ghrelin receptor agonist) at 200 to 300 mcg per injection to amplify the GH pulse without significantly raising cortisol or prolactin. Ipamorelin is the preferred partner because it does not produce the cortisol and ACTH elevation seen with GHRP-2 or GHRP-6.

Pair this peptide schedule with progressive weight-bearing and quadriceps activation exercises beginning at week 4 per your physical therapist's direction.

Phase 3: Remodeling Phase (Weeks 12 to 24)

Continue or transition to CJC-1295 with DAC.

Once the bulk of new collagen is deposited, switching to CJC-1295 with DAC simplifies the schedule and may be better tolerated for longer cycles.

• Dose: 2 mg (2,000 mcg) per injection with DAC.
• Frequency: Once weekly, same day each week, bedtime injection.
• Duration: Continue through week 24 or until return-to-sport clearance, whichever comes first.

Return-to-sport benchmarks in ACL rehabilitation typically require limb symmetry index (LSI) above 90% on isokinetic quadriceps testing and single-leg hop testing. A 2022 meta-analysis in the British Journal of Sports Medicine (k=17 studies, N=1,454) found that athletes who met LSI thresholds above 90% had a re-rupture rate of 3.8%, versus 20.1% in those cleared on time alone without functional testing [7].

Monitoring Labs and Safety Checks

Monitoring is not optional with any GH-axis peptide. The goal is to keep IGF-1 in the upper quartile of the age-matched reference range (roughly 200 to 350 ng/mL for adults aged 25 to 45) without overshooting into supraphysiologic territory.

Baseline Labs (Before Starting)

• Serum IGF-1
• Fasting glucose and HbA1c
• Comprehensive metabolic panel
• Lipid panel
• Testosterone (total and free) for male patients, estradiol for female patients
• Thyroid panel (TSH, free T4)

GH excess at the tissue level can unmask or worsen insulin resistance. Patients with pre-existing prediabetes (HbA1c 5.7 to 6.4%) require more frequent glucose monitoring and should discuss risk/benefit with their prescribing physician before starting.

On-Cycle Monitoring (Every 6 Weeks)

• Serum IGF-1: Target upper quartile for age and sex, not supraphysiologic.
• Fasting glucose: Watch for upward drift above 100 mg/dL.
• HbA1c at 12 weeks.
• Blood pressure: GH-related sodium retention can raise systolic pressure by 5 to 8 mmHg in susceptible individuals.

Dose Adjustment Rules

If IGF-1 exceeds 400 ng/mL at any check, reduce injection frequency by one day per week and recheck in 3 weeks. If IGF-1 exceeds 500 ng/mL, hold the peptide for 2 weeks and recheck before resuming at a lower dose. Sustained supraphysiologic IGF-1 is associated with increased colorectal cancer risk in observational cohort data [8].

Expected Timeline of Outcomes

Collagen remodeling is slow. Patients and clinicians should set realistic expectations.

| Timepoint | Expected Outcome | |-----------|-----------------| | Week 2 to 4 | Subjective improvement in sleep quality (GH pulse during sleep), possible reduction in joint swelling | | Week 6 to 8 | IGF-1 measurably elevated on labs; physical therapy milestones (weight-bearing, ROM) progressing on schedule | | Week 12 | MRI may show increased graft signal homogeneity; quadriceps strength 60 to 70% of contralateral limb | | Week 20 to 24 | Functional testing LSI approaching 85 to 90%; return-to-sport evaluation |

Graft ligamentization (the process by which a tendon graft remodels into ACL-like tissue) takes 12 to 24 months regardless of pharmacologic support. CJC-1295 is not expected to compress that biological timeline dramatically. The more realistic goal is to push collagen quality and quantity toward the upper end of what the biology allows, support muscle preservation during the immobilization period, and reduce systemic catabolism.

A study from the Journal of Bone and Joint Surgery (2023) noted that quadriceps cross-sectional area loss in the first 8 weeks after ACL reconstruction averages 19.3% without intervention [9]. GH/IGF-1 elevation is known to attenuate disuse atrophy; this is arguably the most evidence-supported mechanism by which CJC-1295 may help ACL patients.

Practical Injection Technique

Subcutaneous injection technique matters for consistent absorption.

1. Reconstitute lyophilized CJC-1295 with bacteriostatic water. For a 2 mg vial, add 2 mL of bacteriostatic water to yield a 1,000 mcg/mL solution (or add 4 mL for 500 mcg/mL).
2. Store reconstituted peptide refrigerated at 2 to 8 degrees Celsius. Discard after 28 days.
3. Use a 29-gauge, 0.5-inch insulin syringe.
4. Clean the injection site with an alcohol swab and allow to dry for 15 seconds before injecting.
5. Pinch 1 to 2 cm of subcutaneous tissue and insert the needle at a 45-degree angle.
6. Inject slowly, withdraw the needle, apply light pressure. Do not rub the site.
7. Inject at bedtime, at least 90 minutes after your last meal, to avoid blunting the GH pulse with postprandial insulin.

Alcohol consumption within 2 hours of injection blunts the GH pulse significantly. A controlled study showed that acute ethanol ingestion reduced GH secretion by up to 75% during the nocturnal peak [10].

Who Is Not a Candidate

CJC-1295 is contraindicated or requires significant caution in the following groups:

• Active malignancy or personal history of hormone-sensitive cancer. IGF-1 is a mitogenic signal. The FDA has not approved any GH secretagogue for use in patients with active cancer.
• Uncontrolled type 2 diabetes (HbA1c above 9%). GH is counter-regulatory to insulin; further glucose dysregulation is likely.
• Pregnancy or breastfeeding. No safety data exist.
• Age <18 years. Open growth plates and active endogenous GH axis make exogenous GHRH stimulation inadvisable.
• Acromegaly or pituitary adenoma. Stimulating an already-hyperactive GH axis is dangerous.

Patients with controlled type 2 diabetes (HbA1c <7.5%) may use CJC-1295 cautiously with more frequent glucose monitoring and awareness that dose adjustments to anti-diabetic medications may be needed.

Regulatory and Legal Status

CJC-1295 is not FDA-approved for any indication. In the United States, it may be prescribed by licensed physicians as a compounded medication under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act when compounded by an FDA-registered pharmacy [11]. The FDA has listed several peptides of concern in compounding guidance; CJC-1295 is not currently on the 503A Bulks List as of the most recent FDA interim policy update, which means access through licensed compounding pharmacies has become more restricted in 2024 and 2025.

Patients should verify current compounding pharmacy status directly with their prescribing physician before purchasing. Sourcing peptides from unregulated online vendors bypasses pharmaceutical-grade quality control and introduces contamination risk.

The World Anti-Doping Agency (WADA) prohibits CJC-1295 under the S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics) [12]. Athletes in tested sports should not use it during competition or out-of-competition periods subject to testing.

Stacking CJC-1295 with Other Rehab-Relevant Peptides

Some protocols combine CJC-1295 with other peptides targeting different aspects of connective tissue healing. These combinations are common in sports medicine peptide prescribing, though evidence for the combination is entirely observational.

BPC-157

BPC-157 (Body Protection Compound 157) is a pentadecapeptide derived from a gastric protein sequence. Rat models of Achilles tendon transection showed BPC-157 improved tendon-to-bone healing at 6 weeks [13]. It operates through a distinct mechanism (nitric oxide signaling, VEGF upregulation) and does not interact with the GH axis, making it a non-overlapping stack. Typical dose: 250 to 500 mcg subcutaneously once daily at the site nearest the injury.

TB-500 (Thymosin Beta-4 Fragment)

TB-500 promotes actin polymerization, angiogenesis, and cell migration in injured tissue. A 2021 study in Frontiers in Pharmacology showed TB-500 reduced fibrotic scarring in a rodent muscle injury model [14]. Proponents use it at 2 to 2.5 mg subcutaneously twice per week for 4 to 6 weeks.

The CJC-1295 plus BPC-157 combination is the most commonly prescribed two-peptide ACL stack in sports medicine peptide clinics. CJC-1295 handles systemic anabolic signaling and muscle preservation; BPC-157 targets local tendon and ligament tissue repair.